Launch

Telix begins US commercial launch of Pixclara, the first FDA-approved imaging drug for glioma

What's the news? Telix Pharmaceuticals has begun the US commercial launch of Pixclara (floretyrosine F 18), the first FDA-approved radiopharmaceutical imaging drug for glioma, a type of brain cancer. The first doses were administered on 6 October 2026 at Indiana University Health Neuroscience Center in Indianapolis and University Hospitals Cleveland Medical Center, with Telix's partner PharmaLogic supplying finished unit doses to the US market.

Why it matters: Pixclara is an amino acid positron emission tomography (PET) imaging agent — a radioactive tracer that highlights amino-acid uptake in brain tissue — and the only FDA-approved product of its kind for glioma. It helps physicians tell recurrent or progressive glioma apart from treatment-related change (tissue damage that can mimic tumour growth after radiation therapy) in adults and paediatric patients aged one month and older. The launch follows FDA approval in September 2026 and makes the product commercially available in the US for the first time, addressing an unmet need in brain cancer follow-up imaging.

Read more: Telix Pharmaceuticals via Yahoo Finance, 6 October 2026

More top stories